Member Contact: Dr Rob Crombie
Position: Chief Executive Officer
Industry: Biotech & Pharmaceuticals
QUE Oncology is a clinical stage company developing drugs for large unmet medical needs. The company’s lead drug program, Q-122 is focussed on the treatment of hot flashes in breast cancer survivors undergoing endocrine therapy.
Several clinical studies with Q-122 have shown the drug to be safely administered to over 60 patients and healthy volunteers.
Que Oncology is currently completing further studies and aims to shortly commence a double blinded placebo controlled Phase 2 study in breast cancer patients.
QUE was formed in 2013 through a joint venture between Emory University in Atlanta and the University of Queensland (UQ) research commercialization company, UniQuest.
Backed by a recent A$21.5M capital raise (June 2017) led by Australia’s Medical Research Commercialization Fund (MRCF) and Uniseed, QUE is well funded to execute on its clinical development programs.